Amgen and AstraZeneca Lung Cancer Drug Combination Improves Survival in Late-Stage Trial
📊 AZN — Piyasa Yorumu
▲ up · 60%Positive news that AstraZeneca's lung cancer drug combination improved survival in a late-stage trial could have a short-term positive impact on the stock. However, technical indicators are weak: RSI at 37.7 is near oversold territory, MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. Therefore, upside potential may be limited, and while a relief rally may occur on the news, stronger signals are needed for a trend reversal. A short-term upward move is possible, but the confidence level is moderate.
📊 AMGN — Piyasa Yorumu
▲ up · 55%The positive news could offer short-term support for the stock. However, with a sharp decline of 10.6% over the last 24 hours and the RSI at 14.6, indicating oversold conditions, the potential for a technical rebound increases. The MACD is in negative territory, and the price is below both the 20-day and 50-day moving averages, suggesting a weak overall trend. The news may act as a catalyst for a short-term recovery following the decline, but additional confirmation is needed for a strong upward trend to emerge.
📊 GOOGL — Piyasa Yorumu
■ neutral · 60%The news does not directly affect GOOGL, but positive developments in the healthcare sector could slightly support overall market risk appetite. Technical indicators are mixed: RSI is neutral at 48.5, MACD is negative but close to its signal line, and the price is just below the SMA20 and SMA50. A sideways movement is expected in the short term, with no clear directional signal. Therefore, a neutral outlook is recommended.